A twice-yearly injection described as the most promising HIV prevention tool in decades is poised to reach millions more people.

Dal 2027 lenacapavir, il nuovo antiretrovirale a lunga durata d’azione, sarà disponibile in 120 Paesi a basso e medio reddito. Unitaid, CHAI, Wits RHI e Dr. Reddy’s siglano…

Lenacapavir described as ‘next best thing’ to an HIV vaccine will cost $40 a year for each patient in 120 countries from 2027, funders say